Constance M. Yuan
YOU?
Author Swipe
View article: Phase 2 trial of rituximab with either pentostatin or bendamustine for multiply relapsed or refractory hairy cell leukemia
Phase 2 trial of rituximab with either pentostatin or bendamustine for multiply relapsed or refractory hairy cell leukemia Open
The primary objective in multiply-relapsed hairy cell leukemia and variant (HCL/HCLv) was to determine if pentostatin-rituximab (DCFR) and bendamustine-rituximab (BR) each have overall response rate (ORR) exceeding that historically achiev…
View article: Molecular analysis of bilateral T-cell vitreoretinal lymphoma
Molecular analysis of bilateral T-cell vitreoretinal lymphoma Open
A 63-year-old female who presented with bilateral panuveitis suspicious for a neoplastic etiology, underwent diagnostic pars plana vitrectomy of her right eye. Cytology was negative and flow cytometry did not reveal evidence of B-cell lymp…
View article: Complete Response in Hairy Cell Leukemia to Anti-CD22 CAR T-Cell Therapy
Complete Response in Hairy Cell Leukemia to Anti-CD22 CAR T-Cell Therapy Open
View article: Affinity-matured CD72-targeting Nanobody CAR T-cells Enhance Elimination of Antigen-Low B-cell Malignancies
Affinity-matured CD72-targeting Nanobody CAR T-cells Enhance Elimination of Antigen-Low B-cell Malignancies Open
Background Chimeric antigen receptor (CAR) T-cell therapies are highly efficacious for several different hematologic cancers. However, for most CAR T targets it is observed that low surface antigen density on tumors can significantly reduc…
View article: Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia
Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia Open
Lineage switch (LS), defined as the immunophenotypic transformation of acute leukemia, has emerged as a mechanism of relapse after antigen-targeted immunotherapy, which is associated with dismal outcomes. Through an international collabora…
View article: Non-V600E <i>BRAF</i> mutations and treatment for hairy cell leukemia
Non-V600E <i>BRAF</i> mutations and treatment for hairy cell leukemia Open
We found 20 patients with an immunophenotype consistent with classic hairy cell leukemia and BRAF mutations other than just V600E. Fourteen had 1 non-V600E BRAF mutation and 6 had V600E with 1 (n = 5) or 2 (n = 1) non-V600E BRAF comutation…
View article: <i>CRLF2</i>-rearranged B-cell ALL with extramedullary lineage switch to AML following CD19-targeted therapy
<i>CRLF2</i>-rearranged B-cell ALL with extramedullary lineage switch to AML following CD19-targeted therapy Open
Lineage switch (LS) refers to the immunophenotypic transformation of one leukemia lineage to another (ie, lymphoid to myeloid) with retention of baseline genetics. This phenomenon was originally observed in infants with B-lymphoblastic leu…
View article: COVID-19 vaccination in patients with classic and variant hairy cell leukemia
COVID-19 vaccination in patients with classic and variant hairy cell leukemia Open
Patients with the B-cell malignancy hairy cell leukemia (HCL) and the poorer-prognosis variant HCLv often receive anti-CD20 monoclonal antibodies (mAbs), which kill normal B cells, impairing humoral immunity. We measured COVID-19 antibodie…
View article: Treatment strategies for progressive immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome: case series
Treatment strategies for progressive immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome: case series Open
Not available.
View article: Standardization of flow cytometric detection of antigen expression
Standardization of flow cytometric detection of antigen expression Open
Since response to antigen‐based immunotherapy relies upon the level of tumor antigen expression we developed an antigen quantification assay using ABC values. Antigen quantification as a clinical assay requires methods for quality control …
View article: Rapid anti-myeloma activity by T cells expressing an anti-BCMA CAR with a human heavy-chain-only antigen-binding domain
Rapid anti-myeloma activity by T cells expressing an anti-BCMA CAR with a human heavy-chain-only antigen-binding domain Open
View article: COVID-19 in patients with classic and variant hairy cell leukemia
COVID-19 in patients with classic and variant hairy cell leukemia Open
Hairy cell leukemia (HCL), similar to its variant HCLv, is a B-cell malignancy associated with decreased humoral immunity. We prospectively monitored the largest cohort of patients with HCL/HCLv to date (n = 503) for COVID-19 by symptoms, …
View article: Issue Information
Issue Information Open
View article: Chimeric Antigen Receptor T Cells as Salvage Therapy for Post-Chimeric Antigen Receptor T Cell Failure
Chimeric Antigen Receptor T Cells as Salvage Therapy for Post-Chimeric Antigen Receptor T Cell Failure Open
Outcomes for post-chimeric antigen receptor (CAR) T cell therapy (CART) relapse are poor. The utilization of a unique CAR T cell construct for post-CART failure is increasing, but this approach is not well described. In this study, with CA…
View article: Prolonged voluntary wheel running reveals unique adaptations in mdx mice treated with microdystrophin constructs ± the nNOS-binding site
Prolonged voluntary wheel running reveals unique adaptations in mdx mice treated with microdystrophin constructs ± the nNOS-binding site Open
We tested the effects of prolonged voluntary wheel running on the muscle function of mdx mice treated with one of two different microdystrophin constructs. At 7 weeks of age mdx mice were injected with a single dose of AAV9-CK8-microdystro…
View article: Supplementary Figures and Table from Modulation of Target Antigen Density Improves CAR T-cell Functionality and Persistence
Supplementary Figures and Table from Modulation of Target Antigen Density Improves CAR T-cell Functionality and Persistence Open
Fig S1: Site density cell lines with cytokine analyses of normal healthy donors and patient-derived CD22 CART. Fig S2: Development and evaluation of high-affinity CD22V1 CAR. Fig S3: PKCB2 effects of Bryostatin1 and CD22 modulation with PK…
View article: Supplementary Figures from Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy
Supplementary Figures from Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy Open
Supplementary Figure 1. Uniform CD20 loss from the surface of primary CLL cells after in vivo exposure to ibrutinib. Supplementary Figure 2. Loss of CD20 on ibrutinib and basal CD20 expression levels do not correlate with high risk prognos…
View article: Supplementary Methods from Modulation of Target Antigen Density Improves CAR T-cell Functionality and Persistence
Supplementary Methods from Modulation of Target Antigen Density Improves CAR T-cell Functionality and Persistence Open
Supplementary methods to paper
View article: Supplementary figure 1 from Tumor-Derived GM-CSF Promotes Granulocyte Immunosuppression in Mesothelioma Patients
Supplementary figure 1 from Tumor-Derived GM-CSF Promotes Granulocyte Immunosuppression in Mesothelioma Patients Open
Arginase activity does not drive immunosuppressive granulocyte function
View article: Supplementary tables and figure legends from Disruption of <i>in vivo</i> Chronic Lymphocytic Leukemia Tumor–Microenvironment Interactions by Ibrutinib – Findings from an Investigator-Initiated Phase II Study
Supplementary tables and figure legends from Disruption of <i>in vivo</i> Chronic Lymphocytic Leukemia Tumor–Microenvironment Interactions by Ibrutinib – Findings from an Investigator-Initiated Phase II Study Open
Supplementary Table S1: Evaluation of serum cytokine levels on ibrutinib Supplementary Table S2: Evaluation of chemoattractant levels in bone marrow supernatant on ibrutinib supplementary figure legends for supplementary figures S1-S5
View article: Supplementary figure 2 from Tumor-Derived GM-CSF Promotes Granulocyte Immunosuppression in Mesothelioma Patients
Supplementary figure 2 from Tumor-Derived GM-CSF Promotes Granulocyte Immunosuppression in Mesothelioma Patients Open
Mesothelioma granulocytes suppress T cell activation
View article: Supplementary Figures Legends from Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy
Supplementary Figures Legends from Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy Open
Supplementary Figures Legends from Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy
View article: Data from Tumor-Derived GM-CSF Promotes Granulocyte Immunosuppression in Mesothelioma Patients
Data from Tumor-Derived GM-CSF Promotes Granulocyte Immunosuppression in Mesothelioma Patients Open
Purpose: The cross-talk between tumor cells, myeloid cells, and T cells can play a critical role in tumor pathogenesis and response to immunotherapies. Although the etiology of mesothelioma is well understood, the impact of mesothel…
View article: Supplementary Figs and Tables from Tumor-Derived GM-CSF Promotes Granulocyte Immunosuppression in Mesothelioma Patients
Supplementary Figs and Tables from Tumor-Derived GM-CSF Promotes Granulocyte Immunosuppression in Mesothelioma Patients Open
Supplementary Figs and Tables
View article: Supplementary Figures and Table from Modulation of Target Antigen Density Improves CAR T-cell Functionality and Persistence
Supplementary Figures and Table from Modulation of Target Antigen Density Improves CAR T-cell Functionality and Persistence Open
Fig S1: Site density cell lines with cytokine analyses of normal healthy donors and patient-derived CD22 CART. Fig S2: Development and evaluation of high-affinity CD22V1 CAR. Fig S3: PKCB2 effects of Bryostatin1 and CD22 modulation with PK…
View article: Supplementary figure 3 from Tumor-Derived GM-CSF Promotes Granulocyte Immunosuppression in Mesothelioma Patients
Supplementary figure 3 from Tumor-Derived GM-CSF Promotes Granulocyte Immunosuppression in Mesothelioma Patients Open
Mesothelioma upregulates ROS production by granulocytes
View article: Supplementary Methods from Modulation of Target Antigen Density Improves CAR T-cell Functionality and Persistence
Supplementary Methods from Modulation of Target Antigen Density Improves CAR T-cell Functionality and Persistence Open
Supplementary methods to paper
View article: Supplementary Figs and Tables from Tumor-Derived GM-CSF Promotes Granulocyte Immunosuppression in Mesothelioma Patients
Supplementary Figs and Tables from Tumor-Derived GM-CSF Promotes Granulocyte Immunosuppression in Mesothelioma Patients Open
Supplementary Figs and Tables
View article: Supplementary Table 1 from Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy
Supplementary Table 1 from Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy Open
Supplementary Table 1. Characteristics of all patients studied.
View article: Data from Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy
Data from Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy Open
Purpose: Clinical trials of ibrutinib combined with anti-CD20 monoclonal antibodies (mAb) for chronic lymphocytic leukemia (CLL) report encouraging results. Paradoxically, in preclinical studies, in vitro ibrutinib was report…